Tocotrienol-Rich Fraction Modulates Amyloid Pathology and Improves Cognitive Function in AβPP/PS1 Mice

Nor Faeizah Ibrahim, Daijiro Yanagisawa, Lina Wati Durani, Hamizah Shahirah Hamezah, Mohd Hanafi Ahmad Damanhuri, Wan Zurinah Wan Ngah, Mayumi Tsuji, Yuji Kiuchi, Kenjiro Ono, Ikuo Tooyama

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is the most common cause of dementia. The cardinal neuropathological characteristic of AD is the accumulation of amyloid-β (Aβ) into extracellular plaques that ultimately disrupt neuronal function and lead to neurodegeneration. One possible therapeutic strategy therefore is to prevent Aβ aggregation. Previous studies have suggested that vitamin E analogs slow AD progression in humans. In the present study, we investigated the effects of the tocotrienol-rich fraction (TRF), a mixture of vitamin E analogs from palm oil, on amyloid pathology in vitro and in vivo. TRF treatment dose-dependently inhibited the formation of Aβ fibrils and Aβ oligomers in vitro. Moreover, daily TRF supplementation to AβPPswe/PS1dE9 double transgenic mice for 10 months attenuated Aβ immunoreactive depositions and thioflavin-S-positive fibrillar type plaques in the brain, and eventually improved cognitive function in the novel object recognition test compared with control AβPPswe/PS1dE9 mice. The present result indicates that TRF reduced amyloid pathology and improved cognitive functions, and suggests that TRF is a potential therapeutic agent for AD.

Original languageEnglish
Pages (from-to)597-612
Number of pages16
JournalJournal of Alzheimer's Disease
Volume55
Issue number2
DOIs
Publication statusPublished - 1 Jan 2017

Fingerprint

Tocotrienols
Amyloid
Cognition
Pathology
Alzheimer Disease
Vitamin E
Transgenic Mice
Dementia
Disease Progression
Brain
Therapeutics

Keywords

  • Alzheimer's disease
  • amyloid-β
  • AβPP/PS1 mice
  • tocotrienol-rich fraction
  • Vitamin E

ASJC Scopus subject areas

  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Tocotrienol-Rich Fraction Modulates Amyloid Pathology and Improves Cognitive Function in AβPP/PS1 Mice. / Ibrahim, Nor Faeizah; Yanagisawa, Daijiro; Durani, Lina Wati; Hamezah, Hamizah Shahirah; Ahmad Damanhuri, Mohd Hanafi; Wan Ngah, Wan Zurinah; Tsuji, Mayumi; Kiuchi, Yuji; Ono, Kenjiro; Tooyama, Ikuo.

In: Journal of Alzheimer's Disease, Vol. 55, No. 2, 01.01.2017, p. 597-612.

Research output: Contribution to journalArticle

Ibrahim, NF, Yanagisawa, D, Durani, LW, Hamezah, HS, Ahmad Damanhuri, MH, Wan Ngah, WZ, Tsuji, M, Kiuchi, Y, Ono, K & Tooyama, I 2017, 'Tocotrienol-Rich Fraction Modulates Amyloid Pathology and Improves Cognitive Function in AβPP/PS1 Mice', Journal of Alzheimer's Disease, vol. 55, no. 2, pp. 597-612. https://doi.org/10.3233/JAD-160685
Ibrahim, Nor Faeizah ; Yanagisawa, Daijiro ; Durani, Lina Wati ; Hamezah, Hamizah Shahirah ; Ahmad Damanhuri, Mohd Hanafi ; Wan Ngah, Wan Zurinah ; Tsuji, Mayumi ; Kiuchi, Yuji ; Ono, Kenjiro ; Tooyama, Ikuo. / Tocotrienol-Rich Fraction Modulates Amyloid Pathology and Improves Cognitive Function in AβPP/PS1 Mice. In: Journal of Alzheimer's Disease. 2017 ; Vol. 55, No. 2. pp. 597-612.
@article{72febfb8df8f4cac8ccedfb54968ea4d,
title = "Tocotrienol-Rich Fraction Modulates Amyloid Pathology and Improves Cognitive Function in AβPP/PS1 Mice",
abstract = "Alzheimer's disease (AD) is the most common cause of dementia. The cardinal neuropathological characteristic of AD is the accumulation of amyloid-β (Aβ) into extracellular plaques that ultimately disrupt neuronal function and lead to neurodegeneration. One possible therapeutic strategy therefore is to prevent Aβ aggregation. Previous studies have suggested that vitamin E analogs slow AD progression in humans. In the present study, we investigated the effects of the tocotrienol-rich fraction (TRF), a mixture of vitamin E analogs from palm oil, on amyloid pathology in vitro and in vivo. TRF treatment dose-dependently inhibited the formation of Aβ fibrils and Aβ oligomers in vitro. Moreover, daily TRF supplementation to AβPPswe/PS1dE9 double transgenic mice for 10 months attenuated Aβ immunoreactive depositions and thioflavin-S-positive fibrillar type plaques in the brain, and eventually improved cognitive function in the novel object recognition test compared with control AβPPswe/PS1dE9 mice. The present result indicates that TRF reduced amyloid pathology and improved cognitive functions, and suggests that TRF is a potential therapeutic agent for AD.",
keywords = "Alzheimer's disease, amyloid-β, AβPP/PS1 mice, tocotrienol-rich fraction, Vitamin E",
author = "Ibrahim, {Nor Faeizah} and Daijiro Yanagisawa and Durani, {Lina Wati} and Hamezah, {Hamizah Shahirah} and {Ahmad Damanhuri}, {Mohd Hanafi} and {Wan Ngah}, {Wan Zurinah} and Mayumi Tsuji and Yuji Kiuchi and Kenjiro Ono and Ikuo Tooyama",
year = "2017",
month = "1",
day = "1",
doi = "10.3233/JAD-160685",
language = "English",
volume = "55",
pages = "597--612",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "2",

}

TY - JOUR

T1 - Tocotrienol-Rich Fraction Modulates Amyloid Pathology and Improves Cognitive Function in AβPP/PS1 Mice

AU - Ibrahim, Nor Faeizah

AU - Yanagisawa, Daijiro

AU - Durani, Lina Wati

AU - Hamezah, Hamizah Shahirah

AU - Ahmad Damanhuri, Mohd Hanafi

AU - Wan Ngah, Wan Zurinah

AU - Tsuji, Mayumi

AU - Kiuchi, Yuji

AU - Ono, Kenjiro

AU - Tooyama, Ikuo

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Alzheimer's disease (AD) is the most common cause of dementia. The cardinal neuropathological characteristic of AD is the accumulation of amyloid-β (Aβ) into extracellular plaques that ultimately disrupt neuronal function and lead to neurodegeneration. One possible therapeutic strategy therefore is to prevent Aβ aggregation. Previous studies have suggested that vitamin E analogs slow AD progression in humans. In the present study, we investigated the effects of the tocotrienol-rich fraction (TRF), a mixture of vitamin E analogs from palm oil, on amyloid pathology in vitro and in vivo. TRF treatment dose-dependently inhibited the formation of Aβ fibrils and Aβ oligomers in vitro. Moreover, daily TRF supplementation to AβPPswe/PS1dE9 double transgenic mice for 10 months attenuated Aβ immunoreactive depositions and thioflavin-S-positive fibrillar type plaques in the brain, and eventually improved cognitive function in the novel object recognition test compared with control AβPPswe/PS1dE9 mice. The present result indicates that TRF reduced amyloid pathology and improved cognitive functions, and suggests that TRF is a potential therapeutic agent for AD.

AB - Alzheimer's disease (AD) is the most common cause of dementia. The cardinal neuropathological characteristic of AD is the accumulation of amyloid-β (Aβ) into extracellular plaques that ultimately disrupt neuronal function and lead to neurodegeneration. One possible therapeutic strategy therefore is to prevent Aβ aggregation. Previous studies have suggested that vitamin E analogs slow AD progression in humans. In the present study, we investigated the effects of the tocotrienol-rich fraction (TRF), a mixture of vitamin E analogs from palm oil, on amyloid pathology in vitro and in vivo. TRF treatment dose-dependently inhibited the formation of Aβ fibrils and Aβ oligomers in vitro. Moreover, daily TRF supplementation to AβPPswe/PS1dE9 double transgenic mice for 10 months attenuated Aβ immunoreactive depositions and thioflavin-S-positive fibrillar type plaques in the brain, and eventually improved cognitive function in the novel object recognition test compared with control AβPPswe/PS1dE9 mice. The present result indicates that TRF reduced amyloid pathology and improved cognitive functions, and suggests that TRF is a potential therapeutic agent for AD.

KW - Alzheimer's disease

KW - amyloid-β

KW - AβPP/PS1 mice

KW - tocotrienol-rich fraction

KW - Vitamin E

UR - http://www.scopus.com/inward/record.url?scp=84999268236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84999268236&partnerID=8YFLogxK

U2 - 10.3233/JAD-160685

DO - 10.3233/JAD-160685

M3 - Article

VL - 55

SP - 597

EP - 612

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 2

ER -